Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL27433152 | 0.97 | TP53 (0.44) | TP53CA1CA2CA4CYP3A4 | |
| L-Lactic Acid SCHEMBL6262884 | 0.97 | TP53 (0.44) | TP53CA1CA2CA4CYP3A4 | |
| L-Lactic Acid SCHEMBL30913243 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL186171 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL30837306 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL4360 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL1331114 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL1333089 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL7999572 | 0.96 | TP53 (0.50) | TP53CA1CA2CA4CYP3A4 | |
| L-Lactic Acid SCHEMBL1332699 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 969 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124849-A1 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | BIOMARIN PHARMACEUTICAL INC. (US) | 2024-04-18 | — | — | US | claimed |
| EP-4284441-A1 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | BioMarin Pharmaceutical Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| CN-117042810-A | AAV production systems for AAV viral particles with increased infectivity | 生物马林药物股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| US-11673071-B2 | Isotopic compositions | BOTANICAL WATER TECHNOLOGIES IP LTD (GB) | 2023-06-13 | — | — | US | claimed |
| WO-2022165004-A1 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-08-04 | — | — | WO | claimed |
| US-11266583-B2 | Cosmetic method for treating human perspiration using particles of an expanded amorphous mineral material; compositions | L'OREAL (FR) | 2022-03-08 | — | — | US | claimed |
| US-10993892-B2 | Anhydrous composition in aerosol form comprising an antiperspirant active agent and a water-insoluble film-forming block ethylenic polymer and a phenyl silicone | L'OREAL (FR) | 2021-05-04 | — | — | US | claimed |
| US-10869817-B2 | Antiperspirant stick compositions | Henkel IP & Holding GmbH | 2020-12-22 | — | — | US | claimed |
| US-10835483-B2 | Antiperspirant stick compositions | Henkel IP & Holding GmbH | 2020-11-17 | — | — | US | claimed |
| US-10821068-B2 | Antiperspirant stick compositions | Henkel IP & Holding GmbH (DE) | 2020-11-03 | — | — | US | claimed |
| EP-0943644-A1 | Salt stable cationic silicone oil-in-water microemulsion | DOW CORNING CORPORATION (US) | 1999-09-22 | — | — | EP | claimed |
| EP-0589883-A4 | ENCAPSULATED ANTIPERSPIRANT SALTS AND DEODORANT/ANTIPERSPIRANTS | REVLON (US) | 1997-07-02 | — | — | EP | claimed |
| EP-0589883-A1 | ENCAPSULATED ANTIPERSPIRANT SALTS AND DEODORANT/ANTIPERSPIRANTS | Revlon Consumer Products Corporation (US) | 1994-04-06 | — | — | EP | claimed |
| US-5274152-A | Reacting aqueous sodium hydroxide and aluminum lactate | SOMERVILLE TECHNOLOGY GROUP, INC. (US) | 1993-12-28 | — | — | US | claimed |
| US-5271934-A | Encapsulated antiperspirant salts and deodorant/antiperspirants | REVLON CONSUMER PRODUCTS CORPORATION (US) | 1993-12-21 | — | — | US | claimed |
| US-5194262-A | Water soluble shell wall, bioadhesive for sticking to skin | REVLON CONSUMER PRODUCTS CORPORATION (US) | 1993-03-16 | — | — | US | claimed |
| US-5162378-A | Cetyl dimethicone copolyol, water, silicone, and alcohol; moisturizer, antiperspirant | REVLON CONSUMER PRODUCTS CORPORATION (US) | 1992-11-10 | — | — | US | claimed |
| WO-1992006672-A1 | ENCAPSULATED ANTIPERSPIRANT SALTS AND DEODORANT/ANTIPERSPIRANTS | REVLON, INC. (US) | 1992-04-30 | — | — | WO | claimed |
| US-4524062-A | POWDERED AGENT ENROBED IN COATING MATERIAL | ARMOUR PHARMACEUTICAL COMPANY (US) | 1985-06-18 | — | — | US | claimed |
| US-4252796-A | ALUMINUM COMPOUNDS, ANTIINFLAMMATORY AGENTS | YU RUEY J | 1981-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10993892-B2 | Anhydrous composition in aerosol form comprising an antiperspirant active agent and a water-insoluble film-forming block ethylenic polymer and a phenyl silicone | CUTA, POLR1C, TP53RK | TP53 360/4885CA1 2442/4885CA2 2413/4885 |
| US-11266583-B2 | Cosmetic method for treating human perspiration using particles of an expanded amorphous mineral material; compositions | CUTA, FABP4, SOST | TP53 2165/4885CA1 2274/4885CA2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.